Cytosorbents Corporation (CTSO) vs Citius Pharmaceuticals, Inc. (CTXR)
A side-by-side comparison of Cytosorbents Corporation and Citius Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTSO
Cytosorbents Corporation
$4.03HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
CTXR
Citius Pharmaceuticals, Inc.
$0.49HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT
Total return — CTSO vs CTXR
growth of $100 · dividends reinvested · last 10yCTSO -97.1% (-29.7%/yr)CTXR -99.8% (-46.2%/yr)CTSO compounded faster over this window
Log scale — wide-divergence pair
CTSO CTXR
CTSO vs CTXR: by the numbers
- •CTXR is the larger company ($13M vs $13M market cap).
- •Both run net losses; CTSO's is the smaller (-48.94% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CTSO | CTXR |
|---|---|---|
| P/S ratio | 0.34 | 1.88 |
| P/B ratio | N/A | 0.20 |
Profitability
| Metric | CTSO | CTXR |
|---|---|---|
| Gross margin | 71.61% | 0.00% |
| Operating margin | -33.37% | 0.00% |
| Net margin | -48.94% | -651.27% |
| ROE | N/A | -69.47% |
| ROIC | -43.31% | -67.62% |
Growth (annualized)
| Metric | CTSO | CTXR |
|---|---|---|
| Revenue CAGR (5Y) | -3.17% | N/A |
| Total return CAGR (5Y) | -52.26% | -60.04% |
Frequently asked
- How have CTSO and CTXR total returns compared?
- Over the past 10 years, CTSO delivered -28.72% and CTXR delivered -46.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.